Imbruvica: protein kinase inhibitor with dual indication

Janssen-Cilag has launched Imbruvica (ibrutinib) for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and certain patients with chronic lymphocytic leukaemia (CLL).

by
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK), the first drug in this class. SCIENCE PHOTO LIBRARY
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK), the first drug in this class. SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package